BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be entitled to compensation. The lead plaintiff deadline is November 3, 2026.